)
)
Atreca Investor Relations Material
Latest events
Q4 2022
Atreca
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Atreca Inc
Access all reports
Atreca, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based immunotherapeutics for the treatment of various solid tumor types. Utilizing a novel discovery platform, Atreca's leading product candidate, ATRC-101, is a monoclonal antibody designed with a unique mechanism of action, derived from an antibody identified through this platform. ATRC-101 has demonstrated reactivity in vitro with a wide range of human cancer samples, including ovarian, non-small cell lung, colorectal, and breast cancers. In addition to ATRC-101, Atreca is advancing other product candidates, such as APN-497444, an antibody-drug conjugate (ADC) targeting a novel tumor glycan, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.
Latest articles
)
Mercado Libre: The Digital Backbone of Latin America
From shopping to logistics and fintech, Mercado Libre is shaping the digital transformation of Latin America.
3 Jan 2025
)
House of Pinault: The History and Business of Kering and Gucci
Kering is a luxury group under the Pinault family's leadership, managing iconic brands like Gucci, Saint Laurent, and Bottega Veneta.
19 Dec 2024
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
Ticker symbol
BCEL
Country
🇺🇸 United States